PMC:7534795 / 19597-19916 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T88926","span":{"begin":80,"end":85},"obj":"Body_part"}],"attributes":[{"id":"A47043","pred":"fma_id","subj":"T88926","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T39","span":{"begin":80,"end":85},"obj":"Body_part"}],"attributes":[{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T180","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"T181","span":{"begin":37,"end":47},"obj":"Disease"}],"attributes":[{"id":"A180","pred":"mondo_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A181","pred":"mondo_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T58949","span":{"begin":50,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T48903","span":{"begin":98,"end":100},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T93650","span":{"begin":139,"end":141},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T97130","span":{"begin":161,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T143","span":{"begin":86,"end":88},"obj":"Chemical"},{"id":"T145","span":{"begin":120,"end":131},"obj":"Chemical"},{"id":"T146","span":{"begin":171,"end":182},"obj":"Chemical"}],"attributes":[{"id":"A143","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A144","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A145","pred":"chebi_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-sentences","denotations":[{"id":"T117","span":{"begin":19,"end":47},"obj":"Sentence"},{"id":"T118","span":{"begin":48,"end":68},"obj":"Sentence"},{"id":"T119","span":{"begin":69,"end":90},"obj":"Sentence"},{"id":"T120","span":{"begin":91,"end":131},"obj":"Sentence"},{"id":"T121","span":{"begin":132,"end":192},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T84","span":{"begin":214,"end":219},"obj":"Phenotype"},{"id":"T85","span":{"begin":292,"end":297},"obj":"Phenotype"}],"attributes":[{"id":"A84","pred":"hp_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A85","pred":"hp_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}

{"project":"LitCovid-PubTator","denotations":[{"id":"666","span":{"begin":120,"end":136},"obj":"Chemical"},{"id":"667","span":{"begin":171,"end":182},"obj":"Chemical"},{"id":"678","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"679","span":{"begin":214,"end":219},"obj":"Disease"},{"id":"680","span":{"begin":292,"end":297},"obj":"Disease"}],"attributes":[{"id":"A667","pred":"tao:has_database_id","subj":"667","obj":"MESH:C502936"},{"id":"A678","pred":"tao:has_database_id","subj":"678","obj":"MESH:C000657245"},{"id":"A679","pred":"tao:has_database_id","subj":"679","obj":"MESH:D005334"},{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rolled trial (RCT)\n• Severe COVID-19 infections\n• 18–85 years of age\n• Elevated serum IL-6\n• N = 94 standard therapy + tocilizumab\n• N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once\n• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili"}